Latest News

Patient-reported satisfaction was higher in patients with breast cancer treated with olanzapine vs those who underwent treatment with placebo.
Olanzapine Combo Reduces Chemo-Induced Nausea, Vomiting in Breast Cancer

July 8th 2025

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.
Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

July 8th 2025

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.
Partial-Breast Radiation Appears Effective, Safe in Early Breast Cancer

July 7th 2025

Video Series
Video Interviews
Podcasts
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.
Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

More News